<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Mon, 09 Nov 2009 02:39:00 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Biostar Raises $3.6 Million</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</guid>
      <description><![CDATA[Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614366>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 17:26:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSPM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</link>
    </item>
    <item>
      <title>Bulls Back On Track?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</guid>
      <description><![CDATA[Good morning. With chants of &quot;Dow 10K… Dow 10K&quot; once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614255>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 16:21:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</link>
    </item>
    <item>
      <title>Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</guid>
      <description><![CDATA[Ford's 2,215 page 2007 master contract with the UAW 
1941 UAW-Ford contract<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614051>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 13:52:50 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</link>
    </item>
    <item>
      <title>Your Kind of Day?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</guid>
      <description><![CDATA[As a rule, I try not to read too terribly much into a &quot;Fed Day&quot; as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on &quot;Fed Days.&quot; But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611831>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 19:06:48 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</link>
    </item>
    <item>
      <title>The Dollar-Proof Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</guid>
      <description><![CDATA[Don't put off this important piece of the financial-planning process.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611744>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 17:31:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GLD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IEO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STPZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VEU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VSS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WIP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</link>
    </item>
    <item>
      <title>What Investors Should Look for In Today’s Fed Statement</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</guid>
      <description><![CDATA[In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605772>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 13:04:24 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BCS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ING</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</link>
    </item>
    <item>
      <title>Are Discount Brokers Shares Worth Owning?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</guid>
      <description><![CDATA[The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&amp;P gain 15%.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604683>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 01:28:03 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMTD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ETFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SCHB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</link>
    </item>
    <item>
      <title>Technology Rises And Buying Facebook</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</guid>
      <description><![CDATA[Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%.&#160;&#160; Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601987>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:54:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EBAY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</link>
    </item>
    <item>
      <title>Buffett Gets His Cheque Book Out</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601899</guid>
      <description><![CDATA[Given the slew of positive economic data Monday you might have been forgiven for expecting a decent rebound in risk assets. There was a rebound of sorts in early New York trading, with the Dow up close to 150 points at one stage.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601899>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:17:34 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BNI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">INTC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601899</link>
    </item>
    <item>
      <title>Five Ways To Ride The Commodities Bull</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601726</guid>
      <description><![CDATA[Commodity prices have faltered in the last couple of weeks, and much of the “smart money” is saying the boom is over.
Don’t believe it.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601726>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 15:21:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">VALE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601726</link>
    </item>
    <item>
      <title>Jury convicts N.J. man of southside Lebanon bank robbery</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616993</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 7--A federal jury has convicted a New Jersey man of robbing a southside Lebanon bank more than five years ago, the U.S. Attorney's office reported this week. &lt;/li&gt;&lt;li&gt;The verdict was returned after a three-day trial before U.S. District Court Chief Judge Yvette Kane. &lt;/li&gt;&lt;li&gt;The charges stem from the April 15, 2004, armed robbery of M&amp;T Bank, 837 Quentin Road.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616993>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 07:45:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MTB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616993</link>
    </item>
    <item>
      <title>Carnegie Mellon exhibit blurs line between artist, tools</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3613065</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 5--Art that whispers, learns and evolves is on display at Carnegie Mellon University's recently opened Gates Center for Computer Science. &lt;/li&gt;&lt;li&gt;The class was jointly taught last spring by Carlos Guestrin, an associate professor of computer science and machine learning at Carnegie Mellon's School of Computer Science, and Osman Khan, a visiting associate professor of art in the College of Fine Arts. &lt;/li&gt;&lt;li&gt;The seventh work, &quot;Generation 243,&quot; was created by Scott Draves, a software artist who received his doctorate in 1997 from the computer science department.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3613065>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 03:52:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3613065</link>
    </item>
    <item>
      <title>The News and Advance, Lynchburg, Va., Darrell Laurant Column: A Problem That Needs to Be Addressed</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3577875</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 25--(Second in a series) &lt;/li&gt;&lt;li&gt;To those, let me offer a third -- the certainty that politicians will use taxes as a blunt instrument to wield against their opponents. &lt;/li&gt;&lt;li&gt;This fall, for example, both candidates for Virginia governor are accusing the other of plotting to raise taxes.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3577875>[More...]</a>]]></description>
      <pubDate>Sun, 25 Oct 2009 15:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3577875</link>
    </item>
    <item>
      <title>Catch Up on Tribune Watchdog Reporting: 10 Reports That Got Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3574470</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 23--On Wednesday, the Tribune featured reports updating two of its major watchdog projects this year -- &quot;Clout Goes to College,&quot; which exposed the University of Illinois admissions scandal, and &quot;Compromised Care,&quot; which reported that elderly and disabled nursing home residents were allegedly assaulted, raped and even killed by mentally ill criminals also living in the facilities. &lt;/li&gt;&lt;li&gt;Crestwood's tainted water &lt;/li&gt;&lt;li&gt;What we found: Crestwood's secret use of a polluted well for more than two decades remained secret until April, when the Tribune reported that residents in the southwest suburb unknowingly had been drinking tainted water.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3574470>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 09:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WFMI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3574470</link>
    </item>
    <item>
      <title>MandT Reports 41% Increase in Profits for Third Quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3568337</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 21--M&amp;T Bank Corp. said Tuesday that third-quarter profits rose by 41 percent, fueled by a pair of acquisitions in Maryland, below-average loan losses, a higher profit margin and more fees. &lt;/li&gt;&lt;li&gt;The Buffalo-based bank reported net income of $127.7 million, or 97 cents per share, up from $91.2 million, or 82 cents per share, in the same three-month period a year ago. &lt;/li&gt;&lt;li&gt;That included an after-tax gain of $18 million, or 15 cents per share, from its government-assisted takeover of failed Bradford Bank in the Baltimore area, a transaction through which the Federal Deposit Insurance Corp. will reimburse M&amp;T for most loan losses.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3568337>[More...]</a>]]></description>
      <pubDate>Wed, 21 Oct 2009 15:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MTB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PBKS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3568337</link>
    </item>
    <item>
      <title>MandTreports 41% Increase in Profits for Third Quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3568023</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 21--M&amp;T Bank Corp. said Tuesday that third-quarter profits rose by 41 percent, fueled by a pair of acquisitions in Maryland, below-average loan losses, a higher profit margin and more fees. &lt;/li&gt;&lt;li&gt;The Buffalo-based bank reported net income of $127.7 million, or 97 cents per share, up from $91.2 million, or 82 cents per share, in the same three-month period a year ago. &lt;/li&gt;&lt;li&gt;That included an after-tax gain of $18 million, or 15 cents per share, from its government-assisted takeover of failed Bradford Bank in the Baltimore area, a transaction through which the Federal Deposit Insurance Corp. will reimburse M&amp;T for most loan losses.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3568023>[More...]</a>]]></description>
      <pubDate>Wed, 21 Oct 2009 11:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MTB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PBKS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3568023</link>
    </item>
    <item>
      <title>Novato Study Shows Downtown Business Mix Short on Retail</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3556089</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 15--When it comes to its mix of downtown businesses, Novato is big-time jealous of San Rafael. &lt;/li&gt;&lt;li&gt;Marin's two largest cities have radically different components of their core businesses, as a study by the Novato City Council's Downtown Committee documented this week. &lt;/li&gt;&lt;li&gt;The scorecard: San Rafael has 155 businesses in its downtown area and 81 percent are retail or restaurants; Novato has 196 businesses on Grant Avenue and 33 percent are retail or restaurants.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3556089>[More...]</a>]]></description>
      <pubDate>Fri, 16 Oct 2009 03:52:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WFMI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3556089</link>
    </item>
    <item>
      <title>Roche Deal Lifts SurModics Stock: Eden Prairie Firm Could Take in $200M</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3534201</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 7--Shares of Eden Prairie-based SurModics surged nearly 20 percent Tuesday on word of a licensing and development agreement with pharmaceutical giant Roche and its biotech subsidiary Genentech. &lt;/li&gt;&lt;li&gt;Under the agreement, Roche and Genentech have obtained an exclusive license to use a SurModics system to develop and commercialize a sustained drug delivery formulation of Lucentis, a widely used drug for patients with an eye disorder known as age-related macular degeneration. &lt;/li&gt;&lt;li&gt;The agreement provides Roche and Genentech with opportunities to develop compounds other than Lucentis for the treatment of eye diseases.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3534201>[More...]</a>]]></description>
      <pubDate>Wed, 07 Oct 2009 08:09:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RHHBY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SRDX</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3534201</link>
    </item>
    <item>
      <title>OPINION: Rebuilding Las Vegas</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3493106</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Sep. 20--Is it safe to talk about life after the recession in Las Vegas? &lt;/li&gt;&lt;li&gt;While we're not quite out of the woods and significant economic improvement will likely occur here later than in the rest of the nation, it's time for Nevada, with special emphasis on Las Vegas, to re-imagine the post-recession economy. &lt;/li&gt;&lt;li&gt;Trust your publisher when he tells you that we'll probably never really know how close Las Vegas came to a financial apocalypse in the summer of '09.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3493106>[More...]</a>]]></description>
      <pubDate>Sun, 20 Sep 2009 16:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3493106</link>
    </item>
    <item>
      <title>EDITORIAL: Letters: Hinkle Column Marginalized Minorities</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3476191</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Sep. 13--Satirical Hinkle Column Marginalized Minorities &lt;/li&gt;&lt;li&gt;Editor, Times-Dispatch: The satirical piece by Bart Hinkle, &quot;McDonnell Thesis Barely Scratches the Surface,&quot; was certainly witty. &lt;/li&gt;&lt;li&gt;I can imagine Hinkle chuckling quietly to himself as he wrote.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3476191>[More...]</a>]]></description>
      <pubDate>Sun, 13 Sep 2009 07:50:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3476191</link>
    </item>
    <item>
      <title>Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605706</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company   focused on discovering, developing, and commercializing small molecule   drugs to treat severe medical conditions, today reported financial   results for the quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;In the third quarter, Synta recognized total revenue of $130.4 million,   of which $114.6 million was related to the acceleration of unrecognized   deferred license and milestone revenue in connection with the   termination of the agreement with GlaxoSmithKline for the development of   elesclomol. &lt;/li&gt;&lt;li&gt;General and administrative expenses were $3.1 million for the   third quarter in 2009 compared to $3.7 million for the same period in   2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605706>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CTHP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNTA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605706</link>
    </item>
    <item>
      <title>Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3520640</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today the successful   completion of its acquisition of CuraGen Corporation (Nasdaq: CRGN)   pursuant to the previously disclosed Agreement and Plan of Merger, dated   as of May 28, 2009, by and among CuraGen, Celldex and Celldex's merger   subsidiary, Cottrell Merger Sub, Inc. The Agreement and Plan of Merger   was approved by CuraGen's stockholders and the issuance of shares of   Celldex common stock was approved by Celldex's stockholders at special   stockholder meetings held on September 30, 2009. &lt;/li&gt;&lt;li&gt;Concurrent with the   closing of the merger, Celldex added one position to its Board of   Directors and Dr. Timothy Shannon, President and Chief Executive Officer   of CuraGen, joined the Celldex Board of Directors.&lt;/li&gt;&lt;li&gt;&quot;Celldex is focused on advancing our pipeline of targeted   immunotherapeutics and we look forward to integrating CuraGen's assets   to augment our Precision Targeted Immunotherapy Platform,&quot; stated   Anthony Marucci, President and Chief Executive Officer of Celldex.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3520640>[More...]</a>]]></description>
      <pubDate>Thu, 01 Oct 2009 18:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3520640</link>
    </item>
    <item>
      <title>Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3517478</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Celldex Therapeutics, Inc. (Nasdaq: CLDX) and CuraGen Corporation   (Nasdaq: CRGN) announced that, at special meetings held earlier today,   Celldex's stockholders approved the issuance of shares of Celldex common   stock pursuant to the previously disclosed Agreement and Plan of Merger,   dated as of May 28, 2009, by and among Celldex, Cottrell Merger Sub,   Inc. and CuraGen, and that CuraGen's stockholders approved the Agreement   and Plan of Merger.&lt;/li&gt;&lt;li&gt;Celldex   will issue approximately 16,629,981 shares of its common stock in   exchange for all outstanding shares of CuraGen common stock in   connection with the merger.&lt;/li&gt;&lt;li&gt;About Celldex Therapeutics, Inc.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3517478>[More...]</a>]]></description>
      <pubDate>Wed, 30 Sep 2009 22:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3517478</link>
    </item>
    <item>
      <title>Celldex Therapeutics Announces Appointment of Larry Ellberger As Chairman of the Board</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3459935</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that Larry   Ellberger has been appointed Chairman of the Board of Directors,   effective September 3, 2009. &lt;/li&gt;&lt;li&gt;Mr. Ellberger has been an independent   member of the Celldex Board of Directors since the merger in March 2008   between Celldex and AVANT Immunotherapeutics, Inc., and was a member of   the AVANT Board since 2003. &lt;/li&gt;&lt;li&gt;During his 30 years in the pharmaceutical   and biotechnology industries, Mr. Ellberger had served as Board member   and Chief Executive Officer of PDI, Inc., Chairman of the Board of Omrix   Biopharmaceuticals, Inc. (which was purchased by Johnson &amp; Johnson in   2008), as well as held senior executive positions at W.R. Grace &amp; Co.,   American Cyanamid Company and Powderject Ltd. In addition to his current   position as Founding Partner of HVA, a healthcare transaction advisory   firm, Mr. Ellberger is a Director of TransPharma Medical Ltd. and the   Jewish Children's Museum.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3459935>[More...]</a>]]></description>
      <pubDate>Fri, 04 Sep 2009 20:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GRA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PDII</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3459935</link>
    </item>
    <item>
      <title>Seattle Genetics Announces Exercise of Over-Allotment Option</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3412935</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that the   underwriters of its previously announced public offering of common stock   have exercised in full their option to purchase an additional 1,650,000   shares of common stock. &lt;/li&gt;&lt;li&gt;Seattle Genetics anticipates using the proceeds from this offering to   fund research and development efforts, including manufacturing   activities and clinical trials for its proprietary product candidates,   build-out of a commercial infrastructure and for general corporate   purposes, including working capital.&lt;/li&gt;&lt;li&gt;J.P. Morgan Securities Inc. and Goldman, Sachs &amp; Co. are acting as joint   book-running managers of the offering.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3412935>[More...]</a>]]></description>
      <pubDate>Thu, 13 Aug 2009 14:00:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3412935</link>
    </item>
    <item>
      <title>Seattle Genetics Announces Pricing of Public Offering of Common Stock</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3409628</guid>
      <description><![CDATA[Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $10.75 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $118.2 million. The offering is expected to close on or about August 17, 2009, subject to customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to an aggregate of 1,650,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are being sold by Seattle Genetics.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3409628>[More...]</a>]]></description>
      <pubDate>Tue, 11 Aug 2009 21:44:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3409628</link>
    </item>
    <item>
      <title>Seattle Genetics Announces Proposed Public Offering of Common Stock</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3405247</guid>
      <description><![CDATA[Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Seattle Genetics also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Seattle Genetics. J.P. Morgan Securities Inc. and Goldman, Sachs &amp; Co. are acting as joint book-running managers of the proposed offering.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3405247>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 20:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3405247</link>
    </item>
    <item>
      <title>Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3405683</guid>
      <description><![CDATA[Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3405683>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 13:11:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3405683</link>
    </item>
    <item>
      <title>Clinical Data, Inc. Reports First Quarter Fiscal 2009 Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3403915</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Clinical Data, Inc. (NASDAQ: CLDA) today announced operational and   financial results for the first fiscal quarter ended June 30, 2009.   &lt;/li&gt;&lt;li&gt;The positive results from the second Phase   III trial of vilazodone will contribute to a comprehensive new drug   application (NDA) anticipated to be submitted to the U.S. Food and Drug   Administration (FDA) by year end. &lt;/li&gt;&lt;li&gt;The Company also reported that gross   revenue for Clinical Data's PGxHealth FAMILION&amp;#174;   genetic testing business grew $1.7 million or 81% to $3.7 million   compared to the same period a year ago.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3403915>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3403915</link>
    </item>
    <item>
      <title>ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2009 Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3400389</guid>
      <description><![CDATA[ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the fiscal year and three-month period ended June 30, 2009.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3400389>[More...]</a>]]></description>
      <pubDate>Thu, 06 Aug 2009 20:05:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3400389</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 02  Filed by: CARTER DAVID WARREN (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605757</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605757>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 12:35:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605757</link>
    </item>
    <item>
      <title>Form  4          SEELEY BRUCE J.           For: Oct 30 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599938</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599938>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 23:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599938</link>
    </item>
    <item>
      <title>Form  4          DOBMEIER ERIC             For: Oct 29 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599901</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599901>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 23:25:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599901</link>
    </item>
    <item>
      <title>Form  4/A        SHANNON TIMOTHY M         For: Oct 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533369</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533369>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:53:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533369</link>
    </item>
    <item>
      <title>Form  4/A        Finigan Paul M            For: Oct 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533364</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533364>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:50:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533364</link>
    </item>
    <item>
      <title>Form  4/A        Cassidy Sean A            For: Oct 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533352</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533352>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533352</link>
    </item>
    <item>
      <title>Form  4/A        CURAGEN CORP              For: Oct 01  Filed by: ZENNER PATRICK J (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533349</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533349>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533349</link>
    </item>
    <item>
      <title>Form  4/A        PATRICELLI ROBERT E       For: Oct 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533350</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533350>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533350</link>
    </item>
    <item>
      <title>Form  4/A        Noble James               For: Oct 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533342</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533342>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:45:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533342</link>
    </item>
    <item>
      <title>Form  4/A        FORSGREN JOHN H           For: Oct 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533332</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533332>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 22:44:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533332</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=ADC,ASCO,CLDA,CRGN,DNA,IMGN,MITI,SGEN,SGN,SNTA," rel="self" type="application/rss+xml" />
  </channel>
</rss>